Media
[News] Hua Medicine will present multiple research results at the 2023 American Diabetes Association (ADA) Annual Scientific Sessions
June 16, 2023 - China, Shanghai
Hua Medicine (the "Company", HKEx stock code: 2552) announced today that it will present multiple research results of HuaTangNing (华堂宁®, dorzagliatin), the Company’s first-in-class glucokinase activator (GKA), at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.
The first poster is a preclinical animal studies conducted by Hua Medicine investigating the molecular mechanisms underlying hyperglycemia accompanied by cognitive impairment in diabetic rat model, as well as the potential of low-dose dorzagliatin in preventing glycemic elevation and cognitive dysfunction. The second poster is a translational research jointly conducted by Hua Medicine, Nanjing AscendRare Pharmaceutical Technology (a wholly owned subsidiary company of Hua Medicine), and the University of Pennsylvania. The presentation will compare the impact of dorzagliatin on enzyme of glucokinase (GK) and islet function (including type 2 diabetic human islets and mouse islets) to the other GKAs. The third poster is organized by AscendRare. This poster will discuss the mechanism of diabetes remission with dorzagliatin in an animal model. The fourth poster is a quantitative pharmacology study jointly conducted by Hua Medicine and Peking University Third Hospital to reveal the impact of dorzagliatin on β cell protection in patients with T2DM via quantitatively analytical model.
Additionally, Hua Medicine and AscendRare will present more results through poster presentations, including studies of the mechanisms of hyperammonemia and alterations of amino acid metabolism in a mouse model with knocking of gain-of-function mutation of glutamate dehydrogenase, and the early phase development of new drugs for rare diseases of congenital hyperinsulinism.
A series of films about Hua Medicine and HuaTangNing (华堂宁®), produced by ADA TV and WebsEdge, a famous British media company, will be played across ADA sessions and the media zone.
The ADA Annual Scientific Sessions is the largest and most important diabetes conference in the world. Every year, tens of thousands of researchers and practitioners from all over the world attend this event to report and exchange significant progress in diabetes research and treatment. Since 2014, Hua Medicine and its clinical experts have consistently presented innovative and groundbreaking results of basic and clinical research of dorzagliatin at the ADA Annual Scientific Sessions.
This year's ADA Annual Scientific Sessions will be held in San Diego, USA from June 23rd to 26th, 2023.
Posters of Hua Medicine:
Poster code: 247-LB | |
Title: | Link between hyperglycemia and cognitive deficits in T2DM animal model—Dorzagliatin prevents hyperglycemia and cognitive deficits |
On-site display time: | June 24, 11:30 a.m. - 12:30 p.m. (EST) |
Sessions: | 22-A Integrated Physiology - Central Nervous System Regulation of Metabolism |
Poster code: 293-LB | |
Title: | Dorzagliatin, a glucokinase activator, restores glucose-sensing in type 2 diabetic human islets |
On-site display time: | June 24, 11:30 a.m. - 12:30 p.m. (EST) |
Sessions: | 24-C Islet Biology - Beta Cell - Stimulus-Secretion Coupling and Metabolism |
Poster code: 297-LB | |
Title: | Dorzagliatin, a glucokinase activator, repairs defective islet function in high-fat diet-induced diabetic mice |
On-site display time: | June 24, 11:30 a.m. - 12:30 p.m. (EST) |
Sessions: | 24-C Islet Biology - Beta Cell - Stimulus-Secretion Coupling and Metabolism |
Poster code: 96-LB | |
Title: | Dorzagliatin improves beta-cell function in patients with type 2 diabetes |
On-site display time: | June 24, 11:30 a.m. - 12:30 p.m. (EST) |
Sessions: | 12-D Clinical Therapeutics - Other Therapeutic Agents |
Poster code: 842-P | |
Title: | Development of long-acting GLP-1 receptor antagonist for the treatment of congenital hyperinsulinism |
On-site display time: | June 25, 11:30 a.m. - 12:30 p.m. (EST) |
Sessions: | 12-D Clinical Therapeutics - Other Therapeutic Agents |
Poster code: 1581-P | |
Title: | Systemic alteration of amino acids metabolism in glutamate dehydrogenase gain-of-function mutation knockin mice |
On-site display time: | June 25, 11:30 a.m. - 12:30 p.m. (EST) |
Sessions: | 22-C Integrated Physiology—Liver |
About Hua Medicine
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine will partner with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (华堂宁®) in China, benefiting diabetic patients and their families. HuaTangNing (华堂宁®) has also demonstrated its potential of achieving diabetes remission in clinical studies to help millions of diabetic patients around the world.
For more information
Hua Medicine
Website: www.czfubang.com
Investors
E-mail: ir@czfubang.com
Media
E-mail: pr@czfubang.com
沪ICP备99665955号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
